<DOC>
	<DOCNO>NCT02229175</DOCNO>
	<brief_summary>Currently , diabetic macular edema treat injection medication off-label bevacizumab , decrease swell retina . These injection sometimes require monthly condition control . Recently , new FDA approve treatment use laser decrease swell . These approximately ten minute treatment require injection n't cause permanent damage eye , may decrease number injection one need get treat diabetic macular edema ( DME ) . The purpose randomized clinical trial determine whether subvisible laser combination intravitreal bevacizumab non-inferior compare current standard care ( intravitreal bevacizumab alone ) achieve favorable outcome visual acuity , mean macular thickness , patient quality life , few need intravitreal bevacizumab injection throughout course 12 month study period .</brief_summary>
	<brief_title>Laser v Bevacizumab Injection Alone Treatment Diabetic Macular Edema</brief_title>
	<detailed_description>The patient randomize one two study group describe . - Group 1 : Intravitreal bevacizumab ( IVB ) administer first 3 monthly visit subvisible laser treatment administer first visit . The patient undergo monthly visit , he/she would standard care treatment , allow retreatment monthly IVB laser treatment every 3 month define retreatment criterion meet , determine physician . - Group 2 : Intravitreal bevacizumab ( IVB ) administer first 3 monthly visit . The patient undergo monthly exam , would standard care treatment , allow retreatment monthly IVB define retreatment criterion meet , determine physician . The patient may also undergo sham laser treatment ( he/she place front laser laser activate ) patient n't make aware treatment group he/she part . Other data collect throughout study monthly examination : - Monthly Snellen Visual acuity test - Monthly spectral-domain optical coherence tomography ( SD-OCT ) image use standard clinic protocol monthly - Standard clinic diabetic montage Fundus photos month 0,6,12 - Fluorescein angiography month 0 , 6 , 12 The subject ' visit schedule routine standard care IVB injection procedure . There additional appointment study . All study procedures do San Francisco General Hospital</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Inclusion criterion include adult â‰¥ 18 year type 1 2 diabetes mellitus DME secondary diabetes mellitus involve center macula study eye decrease vision determine primarily result DME study eye . The study eye must BCVA ETDRS letter score 50 24 ( 20/30 20/320 ) study eye . The patient stable medical diabetic regimen expect change . Patients exclude laser photocoagulation ( panretinal macular ) study eye within 90 day Day 1 , two previous macular laser treatment study eye , previous use intraocular periocular corticosteroid study eye within 90 day Day 1 , previous treatment antiangiogenic drug either eye ( pegaptanib sodium , bevacizumab , ranibizumab , aflibercept ) within 45 day Day 1 , active proliferative diabetic retinopathy ( PDR ) study eye , exception inactive , regress PDR , uncontrolled diabetes mellitus , define HbA1c &gt; 12 % , patient functionally monocular , defined clinician vision worse 20/400 fellow eye even eye otherwise eligible study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Diabetic Macular Edema</keyword>
	<keyword>Diabetic Retinopathy</keyword>
	<keyword>Type 1 Diabetes</keyword>
	<keyword>Type 2 Diabetes</keyword>
	<keyword>Macular Edema</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>intravitreal injection</keyword>
	<keyword>Avastin</keyword>
	<keyword>PASCAL Endpoint Management ( EpM ) system</keyword>
	<keyword>Subthreshold focal laser treatment</keyword>
</DOC>